Cargando…

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-...

Descripción completa

Detalles Bibliográficos
Autores principales: Depommier, Clara, Everard, Amandine, Druart, Céline, Plovier, Hubert, Van Hul, Matthias, Vieira-Silva, Sara, Falony, Gwen, Raes, Jeroen, Maiter, Dominique, Delzenne, Nathalie M., de Barsy, Marie, Loumaye, Audrey, Hermans, Michel P., Thissen, Jean-Paul, de Vos, Willem M., Cani, Patrice D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699990/
https://www.ncbi.nlm.nih.gov/pubmed/31263284
http://dx.doi.org/10.1038/s41591-019-0495-2
_version_ 1783444778810081280
author Depommier, Clara
Everard, Amandine
Druart, Céline
Plovier, Hubert
Van Hul, Matthias
Vieira-Silva, Sara
Falony, Gwen
Raes, Jeroen
Maiter, Dominique
Delzenne, Nathalie M.
de Barsy, Marie
Loumaye, Audrey
Hermans, Michel P.
Thissen, Jean-Paul
de Vos, Willem M.
Cani, Patrice D.
author_facet Depommier, Clara
Everard, Amandine
Druart, Céline
Plovier, Hubert
Van Hul, Matthias
Vieira-Silva, Sara
Falony, Gwen
Raes, Jeroen
Maiter, Dominique
Delzenne, Nathalie M.
de Barsy, Marie
Loumaye, Audrey
Hermans, Michel P.
Thissen, Jean-Paul
de Vos, Willem M.
Cani, Patrice D.
author_sort Depommier, Clara
collection PubMed
description Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-related disorders(2). In humans, studies have provided evidence for a negative correlation between Akkermansia muciniphila abundance and overweight, obesity, untreated T2DM, or hypertension(3–8). As the administration of A.muciniphila has never been investigated in humans, we conducted a randomized double-blind placebo-controlled pilot study in overweight/obese insulin resistant volunteers, 40 were enroled and 32 completed the trial. The primary endpoints were on safety, tolerability and metabolic parameters (i.e., insulin resistance, circulating lipids, visceral adiposity, body mass). The secondary outcomes were the gut barrier function (i.e., plasma lipopolysacharrides (LPS) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 10(10) bacteria either alive or pasteurized A.muciniphila for 3 months was safe and well tolerated. Compared to the Placebo, pasteurized A.muciniphila improved insulin sensitivity (+28.62±7.02%, P=0.002), reduced insulinemia (-34.08±7.12%, P=0.006) and plasma total cholesterol (-8.68±2.38%, P=0.02). Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group, and fat mass (-1.37±0.82kg, P=0.092) and hip circumference (-2.63±1.14cm, P = 0.091) as compared to baseline. After 3 months of supplementation, A.muciniphila reduced the levels of relevant blood markers of liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (NCT02637115) shows that the intervention was safe and well-tolerated and that the supplementation with A.muciniphila improves several metabolic paramaters.
format Online
Article
Text
id pubmed-6699990
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-66999902020-01-01 Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Depommier, Clara Everard, Amandine Druart, Céline Plovier, Hubert Van Hul, Matthias Vieira-Silva, Sara Falony, Gwen Raes, Jeroen Maiter, Dominique Delzenne, Nathalie M. de Barsy, Marie Loumaye, Audrey Hermans, Michel P. Thissen, Jean-Paul de Vos, Willem M. Cani, Patrice D. Nat Med Article Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-related disorders(2). In humans, studies have provided evidence for a negative correlation between Akkermansia muciniphila abundance and overweight, obesity, untreated T2DM, or hypertension(3–8). As the administration of A.muciniphila has never been investigated in humans, we conducted a randomized double-blind placebo-controlled pilot study in overweight/obese insulin resistant volunteers, 40 were enroled and 32 completed the trial. The primary endpoints were on safety, tolerability and metabolic parameters (i.e., insulin resistance, circulating lipids, visceral adiposity, body mass). The secondary outcomes were the gut barrier function (i.e., plasma lipopolysacharrides (LPS) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 10(10) bacteria either alive or pasteurized A.muciniphila for 3 months was safe and well tolerated. Compared to the Placebo, pasteurized A.muciniphila improved insulin sensitivity (+28.62±7.02%, P=0.002), reduced insulinemia (-34.08±7.12%, P=0.006) and plasma total cholesterol (-8.68±2.38%, P=0.02). Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group, and fat mass (-1.37±0.82kg, P=0.092) and hip circumference (-2.63±1.14cm, P = 0.091) as compared to baseline. After 3 months of supplementation, A.muciniphila reduced the levels of relevant blood markers of liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (NCT02637115) shows that the intervention was safe and well-tolerated and that the supplementation with A.muciniphila improves several metabolic paramaters. 2019-07-01 2019-07-01 /pmc/articles/PMC6699990/ /pubmed/31263284 http://dx.doi.org/10.1038/s41591-019-0495-2 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Depommier, Clara
Everard, Amandine
Druart, Céline
Plovier, Hubert
Van Hul, Matthias
Vieira-Silva, Sara
Falony, Gwen
Raes, Jeroen
Maiter, Dominique
Delzenne, Nathalie M.
de Barsy, Marie
Loumaye, Audrey
Hermans, Michel P.
Thissen, Jean-Paul
de Vos, Willem M.
Cani, Patrice D.
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title_full Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title_fullStr Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title_full_unstemmed Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title_short Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
title_sort supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699990/
https://www.ncbi.nlm.nih.gov/pubmed/31263284
http://dx.doi.org/10.1038/s41591-019-0495-2
work_keys_str_mv AT depommierclara supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT everardamandine supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT druartceline supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT plovierhubert supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT vanhulmatthias supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT vieirasilvasara supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT falonygwen supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT raesjeroen supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT maiterdominique supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT delzennenathaliem supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT debarsymarie supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT loumayeaudrey supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT hermansmichelp supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT thissenjeanpaul supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT devoswillemm supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy
AT canipatriced supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy